RT Journal Article
SR Electronic
T1 Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.30.22280573
DO 10.1101/2022.09.30.22280573
A1 Tseng, Hung Fu
A1 Ackerson, Bradley K.
A1 Bruxvoort, Katia J.
A1 Sy, Lina S.
A1 Tubert, Julia E.
A1 Lee, Gina S.
A1 Ku, Jennifer H.
A1 Florea, Ana
A1 Luo, Yi
A1 Qiu, Sijia
A1 Choi, Soon Kyu
A1 Takhar, Harpreet S.
A1 Aragones, Michael
A1 Paila, Yamuna D.
A1 Chavers, Scott
A1 Talarico, Carla A.
A1 Qian, Lei
YR 2022
UL http://medrxiv.org/content/early/2022/12/02/2022.09.30.22280573.abstract
AB Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against Omicron BA.4/BA.5 compared with earlier Omicron subvariants. We conducted a test-negative case–control study evaluating mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron subvariants. The study included 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection was high and waned slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection was initially moderate to high (61.0%-90.6% 14-30 days post third dose) and waned rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranged between 64.3%-75.7%, and was low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 was 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 was 88.5%. Evaluation of the updated bivalent booster is warranted.Competing Interest StatementHFT, BKA, LSS, JET, GSL, JHK, AF, YL, SQ, SKC, HST, MA, and LQ are employees of Kaiser Permanente Southern California, which has been contracted by Moderna to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. YDP and SC are employees of and shareholders in Moderna, Inc. HFT received funding from GlaxoSmithKline unrelated to this manuscript; CAT was an employee of and a shareholder in Moderna Inc. at the time of these analyses; CAT is currently an employee of AstraZeneca; HFT also served on advisory boards for Janssen and Pfizer. BKA received funding from GlaxoSmithKline, Dynavax, Genentech, and Pfizer unrelated to this manuscript. KJB received funding from GlaxoSmithKline, Dynavax, Pfizer, and Gilead unrelated to this manuscript. LSS received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. JET received funding from Pfizer unrelated to this manuscript. GSL received funding from GlaxoSmithKline unrelated to this manuscript. JHK received funding from GlaxoSmithKline unrelated to this manuscript. AF received funding from Pfizer, GlaxoSmithKline, and Gilead unrelated to this manuscript. YL received funding from GlaxoSmithKline and Pfizer unrelated to this manuscript. SQ received funding from Dynavax unrelated to this manuscript. SKC received funding from Pfizer and the Pancreatic Cancer Action Network unrelated to this manuscript. HST received funding from GlaxoSmithKline, Pfizer, ALK, and Wellcome unrelated to this manuscript. MA received funding from Pfizer unrelated to this manuscript. LQ received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript.Funding StatementThis study was funded by Moderna, Inc. Employees of Moderna participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. All authors from KPSC had full access to all the data and can take responsibility for integrity of data and accuracy of data analysis. Assistance in writing and formatting of the manuscript were provided by Srividya Ramachandran and Jared Mackenzie of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, and under the direction of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the KPSC Institutional Review Board (IRB #12758). All study staff with access to protected health information were trained in procedures to protect the confidentiality of subject data. A waiver of informed consent was obtained as this is an observational study of authorized and recommended Moderna COVID-19 vaccine administered in the course of routine clinical care. To facilitate the conduct of this study, a waiver was obtained for written HIPAA authorization for research involving use of the EHR.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level data reported in this study are not publicly shared. Upon reasonable request and subject to review, KPSC may provide the de-identified aggregate-level data that support the findings of this study. De-identified data may be shared upon approval of an analysis proposal and a signed data access agreement.